anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A pharmaceutical preparation for the prophylactic treatment of allergies which contains as active ingredient an extract of pollen which contains nor more than 5% by weight, referred to the dry weight of the extract of pollen, of proteins having a high molecular weight or which is completely free of proteins of high molecular weight. The active ingredients of the inventive pharmaceutical preparation have themselves no allergen activity. To those human beings and children which in the years before suffered from severe symptoms of hay fever or asthma, the inventive pharmaceutical preparations were administered, preferably orally, during about three months before the allergy usually had occurred, for instance in the months February until April. By said administration the occurring of the pollen allergy in spring time and during the whole summer could be completely prevented. The inventive pharmaceutical preparations are prepared by extracting the pollen of plants with an aqueous extraction medium, and by metabolizing high molecular proteins of the pollen with a microorganism yielding low molecular proteins or amino acids. Thereafter the aqueous extraction medium is separated from the pollen and the pollen are extracted further with a not aqueous extraction medium. The concentrated extract or the dry residue of the extract recovered with the aqueous medium or the not aqueous medium or a mixture of the extracts or dry residues recovered with the aqueous medium and the not aqueous medium are the active ingredient of the inventive pharmaceutical preparations.
Trabectedin 0.58 mg/m2 administered as a 3-hour intravenous infusion, Days 1, 8, and 15 every 28 days for up to approximately 3 years in the absence of disease progression. Dexamethasone 10 mg administered intravenously 30 minutes prior to each trabectedin infusion.
In acute intestinal ischemia, the progression of ischemia varies across different layers of intestinal tissue. We established a mouse model and used swept-source optical coherence tomography (OCT) to observe the intestinal ischemic process longitudinally in different tissue layers. Employing a method that combines asymmetric gradient filtering with adaptive weighting, we eliminated the vessel trailing phenomenon in OCT angiograms, reducing the confounding effects of superficial vessels on the imaging of deeper vasculature. We quantitatively assessed changes in vascular perfusion density (VPD), vessel length, and vessel average diameter across various intestinal layers. Our results showed a significant reduction in VPD in all layers during ischemia. The mucosa layer experienced the most significant impact, primarily due to disrupted capillary blood flow, followed by the submucosa layer, where vascular constriction or decreased velocity was the primary factor.
Provided in the present invention are a novel NAMPT enzyme agonist and a preparation and a use thereof. The structural formula of the agonist is as shown in formula I or formula II. In the present invention, an NAMPT agonist NAT is screened out from a small molecule chemical library. The NAT exhibits a good cell protection effect, and shows a good anti-neurodegenerative therapeutic effect in animal neurodegeneration models. We studied the binding of the NAT with enzymes, and then performed multiple rounds of structural optimization on the basis of the chemical structural characteristics and enzyme activity characteristics of the NAT, and arrived at a relatively clear structure-activity relationship. The present patent not only lays a foundation for providing innovative drugs for anti-aging and neurodegenerative diseases, but also theoretically provides a proof of concept that enhancing NAMPT enzyme activity plays an important role in neuroprotection.
A facility for providing care to debilitated patients includes a residence area staffed with health care professionals and a plurality of areas having different entertainment themes. The facility can also includes at least one classroom area. The classroom area can, for example, be used to provide instruction at a grade level commensurate with the ability of the patients. The facility also can include at least one restaurant that is handicap accessible. The restaurant can be staffed by at least one trained health care provider or professional (for example, a nurses' aid). Likewise, a plurality of the staff (for example, the servers) can be trained health care providers. The restaurant can be open to the public. The restaurant can also include an area for feeding and care of pets.
Central and systemic inflammation play pivotal roles in epileptogenesis and proepileptogenesis in temporal lobe epilepsy (TLE). The interplay between peripheral CD4+ T cells and central microglia orchestrates the "systemic-central" immune response in TLE. However, the precise molecular mechanisms linking central and systemic inflammation in TLE remain unknown. This preliminary findings revealed an imbalance in Th1/Th2 subsets in the periphery,accompanied by related cytokines release in TLE patients. they proposed that this peripheral Th1/Th2 imbalance may influence central inflammation by mediating microglial state dynamics within epileptic foci and distant brain regions. In Li-pilocarpine-induced TLE rats, a peripheral Th1/Th2 imbalance and observed corresponding central and systemic responses is confirmed. Notably, CD4+ T cells infiltrated through the compromised blood-brain barrierand are spatially close to microglia around epileptic foci. Intravenous depletion and reinfusion of CD4+ T cells modulated microglia state dynamics and altered neuroinflammatory cytokines secretion. Moreover, mRNA sequencing of the human hippocampus identified Notch1 as a key regulator of Th1/Th2 differentiation, CD4+ T cell recruitment to brain infiltration sites, and the regulation of microglial responses, seizure frequency, and cognition. This study underscores the significance of Th1/Th2 imbalance in modulating the "systemic-central" response in TLE, highlighting Notch1 as a potential therapeutic target.
Provided among other things is a topical formulation that comprises: (i) a skin barrier repair formulation comprising lipids that are fatty acid (FA), bilayer-stabilizing steroid (CH), and complex lipid (CL), wherein the skin barrier repair formulation is present in an amount that enhances skin barrier repair, wherein the weight ratio of CL to CH is from about 1.5:1 to about 8:1, and the weight ration of CL to FA is from about 4:1 to about 1:1, the lipids present in an amount from about 3 % wt. to about 10 % wt. of the topical formulation; (ii) one or more retinoids in an amount from about 0.01 % wt. to about 10 % wt. of the topical formulation; (iii) myoinositol, glycine, alanine, taurine or a combination thereof in an amount from about 0.1 % wt. to about 5 % wt of the topical formulation; and (iv) one or more anti-acne acids (such as an alpha hydroxy acid or a beta hydroxy acid) cumulatively in an anti-acne effective amount.
This is a single-arm, single-stage phase II study investigating the use of an individualized dosing regimen of Sunitinib on patients with metastatic renal cell carcinoma. The intent is to maximize dose intensity of sunitinib and minimize time off therapy based on individual tolerability using protocol directed dose modification criteria. Dose and schedule changes are done if toxicity (hematological, fatigue, skin, GI) is \> grade 2. There will be no dosing or schedule changes for hypertension, hypothyroidism, skin color changes, heartburn, etc. unless clinically indicated. Subjects will continue therapy until progression according to RECIST 1.1 criteria. All subjects will be followed for progression free survival until progression but after 2 years on therapy, only grade 3/4 drug related adverse events will be recorded.

Fact-G and FKSI-DRS will be used to evaluate PRO/QOL at baseline and every 2 months timepoints. A more detailed pharmacokinetic blood sampling will be done in a subset of patients in an effort to understand if Sunitinib blood concentration has a tendency to go down during treatment, as has been shown to be the case for Sorafenib. Biomarker and genomics blood sampling for correlation with progression free survival, toxicity and pharmacokinetics will be collected at baseline and stored.
The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity. The carboxamide compounds are compounds of the general formula (I) in which R, R, R, R, R, Q, Y, A and X have the meanings mentioned in the claims and the description, the tautomers thereof and the pharmaceutically suitable salts thereof. In particular, the compounds have the general formula (Ia) and (Ib) in which R, r, R, R, R, R, Y and X have the meanings mentioned in the claims, including the tautomers thereof and the pharmaceutically suitable salts thereof. Of these compounds those are preferred wherein Y is a moiety CH-CH, CH-CH-CH, N(R)-CH2, N(R)-CH-CH or CH=CH-CH=, each optionally having 1 or 2 H-atoms replaced with identical or different radicals R, wherein Rand R have the meanings mentioned in the claims.
OBJECTIVE: To analyze the changes in children's height, weight, BMI and rates of stunting and overweight and obesity over three periods: 1986-1987, 1996-1998, and 2023 for the community of Yalcoba in the Yucatan Peninsula.
MATERIAL AND METHODS: Four hundred forty (6-to-15 years) children measured in 2023 were compared with data obtained in 1986-1987 (n = 675) and 1996-1998 (n = 628). Z-scores of height and BMI were calculated to estimate percentages of stunting and high BMI-for-age (overweight and obesity). Comparisons of anthropometric parameters by sex and age groups between years of measurement were performed through one way ANOVAs.
RESULTS: Differences in anthropometric parameters were significant in all age groups of both sexes. Boys measured in 2023 were, on average, 6.4 and 3.3 cm taller than boys measured in the 1980s and 1990s, respectively. Increases in girls were 12 and 7.3 cm, respectively. Average increases in weight of boys measured in 2023 were 7.9 kg compared to the 1980s and 5.8 kg compared to 1990s. Average increases in girls measured in 2023 were 11.3 kg compared to the 1980s, and 7.6 kg compared to the 1990s. Stunting between the 1980s and 1990s decreased by 15 percentage points and between the 1990s and 2023 decreased by 47 percentage points. The percent of children deemed overweight/obese during these periods increased from 8 to 12-50 by 2023.
CONCLUSION: Results reflect the overall trends seen in the Yucatan where stunting has decreased substantially but the numbers of overweight/obese youths have increased dramatically in the past 30 years.
(1) Vector that on introduction into a suitable bacterial host cell contg. the thermolabile repressor C (I) renders the host cell capable, when the temp. is raised to a level at which the repressor is inactivated, of effecting expression of a desired gene inserted in the vector to produce polypeptide (I) encoded by the gene is new when it comprises a double-stranded DNA molecule including in 5'- to 3'- order. (a) DNA sequence contg. the promoter and operator P(L)O(L) from lambda bacteriophage; (b) a N utilisation site for binding antiterminator N protein; (c) a first restriction enzyme site permitting replacement of the DNA sequence contg. the ribosomal binding site following after; (d) DNA sequence contg. a ribosomal binding site for making the MRNA of the desired gene capable of binding to ribosomes in the host cell; (e) ATG initiator codon or a DNA sequence converted into the codon on insertion of the desired gene into the vector; and (f) a second restriction enzyme site for inserting the desired gene into the vector in phase with the ATG initiation codon; and (g) a DNA sequence contg. an origin of replication from a bacterial plasmid capable of autonomous replication in the host cell; and for selection, DNA sequence contg. a gene associated with a selectable or identifiable phenotypic trait manifested when the vector is present in the host cell, or DNA sequence contg. fragment C (I) 434, including the gene for the C (I) 434 repressor protein and its associated promoter and operator sequence.
Mecamylamine, a secondary amine, readily penetrates into the brain and thus may produce central nervous system effects. Tremor, choreiform movements, mental aberrations, and convulsions may occur rarely. These have occurred most often when large doses of INVERSINE1 were used, especially in patients with cerebral or renal insufficiency.

When ganglion blockers or other potent antihypertensive drugs are discontinued suddenly, hypertensive levels return. In patients with malignant hypertension and others, this may occur abruptly and may cause fatal cerebral vascular accidents or acute congestive heart failure. When INVERSINE1 is withdrawn, this should be done gradually and other antihypertensive therapy usually must be substituted. On the other hand, the effects of INVERSINE1 sometimes may last from hours to days after therapy is discontinued.
A group of 20 patients with stage 5 Chronic Kidney Disease (estimated glomerular filtration rate \<15 ml/min/m2), who attend chronic hemodialysis treatments at The Ottawa Hospital (TOH) will be invited to participate. Measurements of arterial stiffness will be performed in this group by Applanation tonometry.
External beam radiotherapy (EBRT) is routinely available at regional cancer centres across the UK. For palliation of dysphagia in oesophageal cancer, a radiotherapy course delivering a tumour absorbed dose of 20Gy in 5 fractions or 30Gy in 10 fractions within 4 weeks of SEMS insertion.
Physical dependence is not ordinarily a concern in the treatment of patients with chronic cancer pain, and fear of tolerance and physical dependence must not deter using opiate doses that adequately relieve the pain. Guide the administration of Abstral by the response of the patient.

Opioid analgesics may cause physical dependence that can result in withdrawal symptoms in patients who abruptly discontinue the drug. Withdrawal also may be precipitated through the administration of drugs with opioid antagonist activity (e.g., naloxone, nalmefene) or mixed agonist/antagonist analgesics (pentazocine, butorphanol, buprenorphine, nalbuphine).

Physical dependence usually does not occur to a clinically significant degree until after several weeks of continued opioid usage. Tolerance, in which increasingly larger doses are required in order to produce the same degree of analgesia, is initially manifested by a shortened duration of analgesic effect, and subsequently, by decreases in the intensity of analgesia.
Migraine is a benign and frequent disorder. Migraine aura consists in reversible focal neurological symptoms developing gradually during attack. Its diagnosis relies mainly on patient's history, clinical examination and exclusion of other possible secondary causes to explain transient neurological signs. Thus it can be difficult particularly during first attack or during attack without headache to differentiate migraine aura from transient ischemic stroke. Considering the difference of care management and prognosis, an early distinction of migraine aura based on imaging techniques will have a particular interest. MRI with diffusion, SWI, Flair 2D, ARM 3D TOF, ASL sequences' are routinely performed for the management of acute neurological deficit. Arterial spin labeling (ASL), as a MR perfusion method, will be used to describe brain perfusion during migraine aura. The study hypothesis is that hyperperfusion occurs in brain territories corresponding to the neurological symptoms during migraine aura.
We developed a mobile application to promote healthy lifestyles and collect non-communicable disease (NCD) data in Mexico. Its theoretical foundations are supported by a framework-guided literature review. With design sprints, Scrum, Model-View-Controller, and Representational State Transfer architecture, we operationalized evidence-based nutrition/physical activity information into a crowdsourcing- and gamification-based application. The application was piloted for three months to monitor the response of 520 adults. Potential improvements were characterized, considering benchmarking, expert guidance, and standards. Salud Activa (English: Active Health) has two crowdsourcing modules: Nutritional scanner, scanning products' bar codes, providing nutritional data, and allowing new product registry feeding our databases; Surveys, comprising gradually-released NCD questions. Three intervention modules were generated: Drinks diary, a beverage assessment component to receive hydration recommendations; Step counter, monitoring users' steps via Google Fit/Health-iOS; Metabolic Avatar, interconnecting modules and changing as a function of beverage and step records. The 3-month median of Salud Activa use was seven days (IQR = 3-12), up to 35% of participants completed a Survey section, and 157 food products were registered through Nutritional scanner. Better customization might benefit usability and user engagement. Quantitative and qualitative data will enhance Salud Activa's design, user uptake, and efficacy in interventions delivered through this platform.
Ascites and pleural effusion are recognized complications of pancreatic cancer. These diseases are accompanied by ascites and pleural effusion, and drug treatment is limited by high costs, long hospital stays, and failure rates. Immunotherapy may offer new option, but in most patients with late stages of cancer, immune cells may lose the ability to recognize tumor cells, how to activate their immune cells is a major problem, sodium glucosidate (SSG) is injected into ascites as a protein tyrosine phosphatase inhibitor to wake up immune cells and prepare for immunotherapy. We used single-cell RNA sequencing (scRNA-seq) to investigate whether and how SSG injected into ascites of pancreatic cancer elicits an immune response. Our study showed that the process of SSG fusion treatment of ascites and pleural effusion, the interaction between TandNK cells, MPs cells, monocytes and neutrophils was induced, and large numbers of genes were expressed, resulting in upregulation of immune response, which also approved that SSG is not only used as a protein tyrosine phosphatase inhibitor, but also it works as a protein tyrosine phosphatase inhibitor. It can also be used to regulate immune cell function, recruiting immune cells to the right place with the help of PD-1 or PD-L1 to fight cancer cells in ascites and pleural effusions in cancer patients.
Embodiments herein describe systems and methods for scalable mapping of brain dynamics and uses thereof are provided. Many embodiments are capable of mapping brain dynamics in a computationally efficient way. In many embodiments, shape graphs can be produced which can operate as interactive network representations of dynamic brain activity data. Methods for automatically interpreting the structure of the shape graphs are described herein. In various embodiments, the mapped brain dynamics can be used to indicate which type of treatment protocol is likely to be most effective for the particular individual. In many embodiments, the treatment includes transcranial magnetic stimulation, pharmaceutical treatment, and/or any other mental condition treatment as appropriate to the requirements of specific applications of embodiments of the invention.
Plants use nucleotide-binding leucine-rich repeat receptors (NLRs) to sense pathogen effectors, initiating effector-triggered immunity (ETI). NLRs containing RESISTANCE TO POWDERY MILDEW 8 domain (RNLs) function as "helper" NLRs in flowering plants and support the immune responses mediated by "sensor" NLRs in cooperation with lipase-EP domain fused proteins (EP proteins). Despite their crucial roles in ETI, much remains unclear about the evolutionary trajectories of RNLs and their functional partners EP proteins. Here, we perform phylogenomic analyses of RNLs in 90 plants, covering the major diversity of plants, and identify the presence of RNLs in land plants and green algae, expanding the distribution of RNLs. We uncover a neglected major RNL group in gymnosperms, besides the canonical major group with NRG1s and ADR1s, and observe a drastic increase in RNL repertoire size in conifers. Phylogenetic analyses indicate that RNLs originated multiple times through domain shuffling, and the evolution of RNLs underwent a birth-and-death process. Moreover, we trace the origin of EP proteins back to the last common ancestor of vascular plants. We find that both RNLs and EP proteins evolve mainly under negative selection, revealing strong constraints on their function. Concerted losses and positive correlation in copy number are observed between RNL and EP sublineages, suggesting their cooperation in function. Together, our findings provide insights into the origin and evolution of plant helper NLRs, with implications for predicting novel innate immune signaling modules.
This is a phase 2, study in which 14 MDS patients with Trisomy 8 or classified as Intermediate-1, -2 and High risk who meet all other inclusion/exclusion criteria will receive ON 01910.Na 800 mg/m\^2/24h as an continuous intravenous infusion (CIV) over 48 hours once a week for 3 weeks of a 4-week cycle. As of Amendment 3 to the Protocol, the regimen is changed to 1800 mg/24h for 72 hours every other week for the first four 2-week cycles and every 4 weeks afterwards. The total study duration is 31 weeks, which includes a 2-week screening phase, a 27-week dosing phase, and a 4-week follow-up phase that begins after the last dose of ON 01910.Na. Beginning at week 4, and every 2 weeks thereafter, patients will be assessed for response. Patients who drop out for any reason will not be replaced. Patients who achieve by week 29 a complete or partial response or stabilization of their disease are eligible to receive an additional 24 weeks of ON 01910.Na 1800 mg/24 h over 72 hours per week of a 4-week cycle.
The present invention provides the complete genomic sequence of a novel human coronavirus, coined as human coronavirus- HKU1 (''HCoV-HKU1''), isolated in Hong Kong. The virus belongs to the order Nidovirales of the family Coronaviridae, being a single-stranded RN virus of positive polarity. Futher study on nasopharyngeal aspirates from patients with community-acquired pnbeumonia has revealed that there are two genotypes, genotype A and genotype B, for this virus. In addition to the genomic sequences of these two genotypes, the invention provides the deduced amino acid sequences of the complete genome of the CoV-HKU1. The nucleotide sequences and deduced amino acid sequences of the HCoV-HKU1are useful in preventing, diagnosing and/or treating the infection by HCoV-HKU1. Furthermore, the invention provides immunogenic and vaccine preparations using recombinant and chimeric forms as well as subunits of the HCoV- HKU1 based on the nucleotide sequences and deduced amino acid sequences of the HCoV-HKU1.
We will observe the risk for islet autoimmunity in the offspring where the mother has type 1 diabetes. There is no intervention in this study.